Anti cd137 pecy7

Manufactured by BioLegend

Sourced in United States

Anti-CD137 PECy7 is a fluorochrome-conjugated antibody that targets the CD137 surface marker. CD137, also known as 4-1BB, is a co-stimulatory molecule expressed on activated T cells and natural killer cells. This antibody can be used in flow cytometry applications to identify and analyze cells expressing CD137.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using anti cd137 pecy7

Multiparametric Immune Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-HLA-A*02 APC (RRID AB 2561567, clone BB7.2), anti-CD3 PerCPCy5.5 (RRID AB 2561628, clone OKT3) and PE (RRID AB 571913, clone OKT3), anti-CD8 FITC (RRID AB 1877178, clone SK1), anti-CD137 PECy7 (RRID AB 2207741, clone 4B4-1), anti-CD45RO PECy7 (RRID AB 11203903, clone UCHL1), anti-CD45RA PerCPCy5.5 (RRID AB 893358, clone HI100), anti-CCR7 APC-Cy7 (RRID AB 10915272, clone G043H7) were bought from Biolegend (San Diego, CA, USA).

Quiros-Fernandez I., Poorebrahim M., Fakhr E, & Cid-Arregui A. (2021). Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals. EBioMedicine, 72, 103610.

+ Open protocol

+ Expand

T-Cell Phenotyping Protocol by Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols

T-cell phenotype was performed by FC employing the following monoclonal antibodies (MoAbs): anti-CD3-BV510 (BioLegend, 317,332), anti-CD4-ApcH7 (BD, 560,158), anti-CD8-Percp5.5 (BioLegend, 344,710), anti-CCR7-FITC (BioLegend, 353,216), anti-CD45RA-Apc (BioLegend, 304,112), anti-PD-1-PE (BioLegend, 621,608), anti-IgM-BV421 (BioLegend, 314,516), anti-CD137-PeCy7 (BioLegend, 309,818) and 7-AAD (BD, 559,925). Cells were incubated with FC-block (BioLegend, 101,302) for 5 min and surface staining was performed at 4 °C for 15 min. At least 10⁴ events were evaluated using a FACSCantoII flow cytometer.

Ugolini A., Zizzari I.G., Ceccarelli F., Botticelli A., Colasanti T., Strigari L., Rughetti A., Rahimi H., Conti F., Valesini G., Marchetti P, & Nuti M. (2020). IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells. EBioMedicine, 62, 103098.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!